Abstract:In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–activity relationship though cyclization modification based on previously reported compound 18e led to the discovery of the superior derivative 13ac. Compound 13ac showed excellent potency on JAK2 kinase, SET-2, and Ba/F3V617F cells (high expression of JAK2V617F mutation) with IC50 values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound 13ac could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound 13ac also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, 13ac significantly ameliorated the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01488?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01488</a>.Binding affinities of 13ac with 365 protein kinases;1H NMR, 13C NMR, MS/MS, and HPLC spectra of compound 13ac; routine blood test in normal mice; and effect of 13ac on mouse models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf">PDF</a>)PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a> used for modeling docking in JAK2 of 13ac (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_002.pdb">PDB</a>)PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a> used for modeling docking in FLT3 of 18e (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_003.pdb">PDB</a>)(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_004.pdb">PDB</a>)Molecular formula strings of the prepared compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_005.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)

Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

2-Aminopyrimidine derivatives as selective dual inhibitors of JAK2 and FLT3 for the treatment of acute myeloid leukemia

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine Derivatives As Type-II Inhibitors of FLT3 Selective Against C-Kit

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

N -(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

Discovery and Anticancer Screening of Novel Oxindole-Based Derivative Bearing Pyridyl Group as Potent and Selective Dual FLT3/CDK2 Kinase Inhibitor

Rational Design of 4-((6-phenoxypyrimidin-4-yl)amino)-n-(4-(piperazin-1-yl)phenyl)-1h-pyrazole-3-carboxamide (LT-540-717) As Orally Bioavailable FLT3 Inhibitor

Discovery of 1-(4-(4-amino-3-(4-(2-morpholinoethoxy)phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) As a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia

Discovery of Imidazopyrrolopyridines Derivatives As Novel and Selective Inhibitors of JAK2.

Design and Synthesis of Novel Pyrrolo[2,3-D]pyrimidine Derivatives As Potent JAK3 and SYK Dual Inhibitors

Design and Synthesis of Selective FLT3 Inhibitors Via Exploration of Back Pocket II